Department of Civil and Environmental Engineering, University of California Los, Angeles, Los Angeles, CA 90095, USA.
Department of Civil and Environmental Engineering, University of California Los, Angeles, Los Angeles, CA 90095, USA; Institute of the Environment and Sustainability, University of California Los, Angeles, Los Angeles, CA 90095, USA.
J Environ Manage. 2014 Apr 1;136:112-20. doi: 10.1016/j.jenvman.2014.01.029. Epub 2014 Feb 26.
Some molecular methods for tracking fecal pollution in environmental waters have both PCR and quantitative PCR (qPCR) assays available for use. To assist managers in deciding whether to implement newer qPCR techniques in routine monitoring programs, we compared detection limits (LODs) and costs of PCR and qPCR assays with identical targets that are relevant to beach water quality assessment. For human-associated assays targeting Bacteroidales HF183 genetic marker, qPCR LODs were 70 times lower and there was no effect of target matrix (artificial freshwater, environmental creek water, and environmental marine water) on PCR or qPCR LODs. The PCR startup and annual costs were the lowest, while the per reaction cost was 62% lower than the Taqman based qPCR and 180% higher than the SYBR based qPCR. For gull-associated assays, there was no significant difference between PCR and qPCR LODs, target matrix did not effect PCR or qPCR LODs, and PCR startup, annual, and per reaction costs were lower. Upgrading to qPCR involves greater startup and annual costs, but this increase may be justified in the case of the human-associated assays with lower detection limits and reduced cost per sample.
一些用于追踪环境水中粪便污染的分子方法都有 PCR 和定量 PCR(qPCR)检测可供使用。为了帮助管理者决定是否在常规监测计划中采用更新的 qPCR 技术,我们比较了针对海滩水质评估相关的相同目标的检测限(LOD)和 PCR 与 qPCR 检测的成本。对于针对拟杆菌 HF183 遗传标记的人类相关检测,qPCR 的 LOD 低了 70 倍,并且目标基质(人工淡水、环境溪流水和环境海水)对 PCR 或 qPCR 的 LOD 没有影响。PCR 的启动和年度成本最低,而每个反应的成本比基于 Taqman 的 qPCR 低 62%,比基于 SYBR 的 qPCR 高 180%。对于海鸥相关的检测,PCR 和 qPCR 的 LOD 之间没有显著差异,目标基质对 PCR 或 qPCR 的 LOD 没有影响,PCR 的启动、年度和每个反应的成本都较低。升级到 qPCR 需要更高的启动和年度成本,但对于检测限更低、每个样本成本更低的人类相关检测,这种增加可能是合理的。